Click here to get full coverage on Chardan Capital Reaffirms Buy Rating for Immatics (NASDAQ:IMTX) - MarketBeat

Chardan Capital Reaffirms Buy Rating for Immatics (NASDAQ:IMTX)  MarketBeat

Chardan Capital Reaffirms Buy Rating for Immatics (NASDAQ:IMTX) - MarketBeat

Click here to get full coverage on Chardan Capital Maintains Immatics N.V. (IMTX) Buy Recommendation - Nasdaq

Chardan Capital Maintains Immatics N.V. (IMTX) Buy Recommendation  Nasdaq

Chardan Capital Maintains Immatics N.V. (IMTX) Buy Recommendation - Nasdaq

Click here to get full coverage on Immatics (NasdaqCM:IMTX) Valuation Spotlight After Q3 Net Loss Expands - simplywall.st

Immatics (NasdaqCM:IMTX) Valuation Spotlight After Q3 Net Loss Expands  simplywall.st

Immatics (NasdaqCM:IMTX) Valuation Spotlight After Q3 Net Loss Expands - simplywall.st

Click here to get full coverage on IMTX: Chardan Capital Maintains Buy Rating with $25 Target | IMT - GuruFocus

IMTX: Chardan Capital Maintains Buy Rating with $25 Target | IMT  GuruFocus

IMTX: Chardan Capital Maintains Buy Rating with $25 Target | IMT - GuruFocus

Click here to get full coverage on (IMTX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com

(IMTX) Price Dynamics and Execution-Aware Positioning  news.stocktradersdaily.com

(IMTX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com

Click here to get full coverage on Evaluating Immatics (NasdaqCM:IMTX) Valuation After Recent Volatility and Sector Momentum - Yahoo Finance

Evaluating Immatics (NasdaqCM:IMTX) Valuation After Recent Volatility and Sector Momentum  Yahoo Finance

Evaluating Immatics (NasdaqCM:IMTX) Valuation After Recent Volatility and Sector Momentum - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $IMTX Given $19.0 Price Target - Quiver Quantitative

New Analyst Forecast: $IMTX Given $19.0 Price Target  Quiver Quantitative

New Analyst Forecast: $IMTX Given $19.0 Price Target - Quiver Quantitative

Click here to get full coverage on Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 (NASDAQ:IMTX) - Seeking Alpha

Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 (NASDAQ:IMTX)  Seeking Alpha

Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 (NASDAQ:IMTX) - Seeking Alpha

Click here to get full coverage on Will IMTX bounce back from current support - Quarterly Trade Summary & Community Consensus Trade Alerts - newser.com

Will IMTX bounce back from current support - Quarterly Trade Summary & Community Consensus Trade Alerts  newser.com

Will IMTX bounce back from current support - Quarterly Trade Summary & Community Consensus Trade Alerts - newser.com

Click here to get full coverage on Should Immatics' (IMTX) New Clinical Data on IMA402 and IMA401 Prompt Fresh Investor Attention? - Yahoo Finance

Should Immatics' (IMTX) New Clinical Data on IMA402 and IMA401 Prompt Fresh Investor Attention?  Yahoo Finance

Should Immatics' (IMTX) New Clinical Data on IMA402 and IMA401 Prompt Fresh Investor Attention? - Yahoo Finance

Click here to get full coverage on IMTX Stock Sees Raised Price Target by Mizuho Analyst | IMTX Sto - GuruFocus

IMTX Stock Sees Raised Price Target by Mizuho Analyst | IMTX Sto  GuruFocus

IMTX Stock Sees Raised Price Target by Mizuho Analyst | IMTX Sto - GuruFocus

Click here to get full coverage on Immatics (NASDAQ:IMTX) Shares Up 6.7% Following Analyst Upgrade - MarketBeat

Immatics (NASDAQ:IMTX) Shares Up 6.7% Following Analyst Upgrade  MarketBeat

Immatics (NASDAQ:IMTX) Shares Up 6.7% Following Analyst Upgrade - MarketBeat

Click here to get full coverage on PRAME Oncology Advances Could Be a Game Changer for Immatics (IMTX) - simplywall.st

PRAME Oncology Advances Could Be a Game Changer for Immatics (IMTX)  simplywall.st

PRAME Oncology Advances Could Be a Game Changer for Immatics (IMTX) - simplywall.st

Click here to get full coverage on Here's Why We're Not Too Worried About Immatics' (NASDAQ:IMTX) Cash Burn Situation - Yahoo Finance

Here's Why We're Not Too Worried About Immatics' (NASDAQ:IMTX) Cash Burn Situation  Yahoo Finance

Here's Why We're Not Too Worried About Immatics' (NASDAQ:IMTX) Cash Burn Situation - Yahoo Finance

Click here to get full coverage on IMTX: Guggenheim Raises Price Target Amidst Consistent 'Buy' Rat - GuruFocus

IMTX: Guggenheim Raises Price Target Amidst Consistent 'Buy' Rat  GuruFocus

IMTX: Guggenheim Raises Price Target Amidst Consistent 'Buy' Rat - GuruFocus

Click here to get full coverage on Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates - Nasdaq

Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates  Nasdaq

Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates - Nasdaq

Click here to get full coverage on Can Immatics' (IMTX) TCR Bispecifics Reveal Shape the Future of Its Innovation Strategy? - simplywall.st

Can Immatics' (IMTX) TCR Bispecifics Reveal Shape the Future of Its Innovation Strategy?  simplywall.st

Can Immatics' (IMTX) TCR Bispecifics Reveal Shape the Future of Its Innovation Strategy? - simplywall.st

Click here to get full coverage on Immatics (NASDAQ:IMTX) Price Target Raised to $19.00 at Guggenheim - MarketBeat

Immatics (NASDAQ:IMTX) Price Target Raised to $19.00 at Guggenheim  MarketBeat

Immatics (NASDAQ:IMTX) Price Target Raised to $19.00 at Guggenheim - MarketBeat

Click here to get full coverage on A Fresh Look at Immatics (IMTX) Valuation Following Promising Phase 1a Clinical Results - simplywall.st

A Fresh Look at Immatics (IMTX) Valuation Following Promising Phase 1a Clinical Results  simplywall.st

A Fresh Look at Immatics (IMTX) Valuation Following Promising Phase 1a Clinical Results - simplywall.st

Click here to get full coverage on Immatics (NASDAQ: IMTX) posts Q3 2025 with $505.8M cash and PRAME pipeline progress - Stock Titan

Immatics (NASDAQ: IMTX) posts Q3 2025 with $505.8M cash and PRAME pipeline progress  Stock Titan

Immatics (NASDAQ: IMTX) posts Q3 2025 with $505.8M cash and PRAME pipeline progress - Stock Titan

Click here to get full coverage on Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX) - Yahoo Finance

Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX)  Yahoo Finance

Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX) - Yahoo Finance

Click here to get full coverage on Strategies to average down on IMTX - Earnings Summary Report & Detailed Earnings Play Alerts - newser.com

Strategies to average down on IMTX - Earnings Summary Report & Detailed Earnings Play Alerts  newser.com

Strategies to average down on IMTX - Earnings Summary Report & Detailed Earnings Play Alerts - newser.com

Click here to get full coverage on Immatics (NASDAQ: IMTX) names Amie Krause CPO to lead HR amid commercial-stage transition - Stock Titan

Immatics (NASDAQ: IMTX) names Amie Krause CPO to lead HR amid commercial-stage transition  Stock Titan

Immatics (NASDAQ: IMTX) names Amie Krause CPO to lead HR amid commercial-stage transition - Stock Titan

Click here to get full coverage on Immatics (NASDAQ:IMTX) Given New $23.00 Price Target at Mizuho - MarketBeat

Immatics (NASDAQ:IMTX) Given New $23.00 Price Target at Mizuho  MarketBeat

Immatics (NASDAQ:IMTX) Given New $23.00 Price Target at Mizuho - MarketBeat

Click here to get full coverage on Guggenheim Initiates Coverage of Immatics N.V. (IMTX) with Buy Recommendation - Nasdaq

Guggenheim Initiates Coverage of Immatics N.V. (IMTX) with Buy Recommendation  Nasdaq

Guggenheim Initiates Coverage of Immatics N.V. (IMTX) with Buy Recommendation - Nasdaq

Click here to get full coverage on Immatics: Q3 Earnings Snapshot - CT Insider

Immatics: Q3 Earnings Snapshot  CT Insider

Immatics: Q3 Earnings Snapshot - CT Insider

Click here to get full coverage on Immatics (NASDAQ: IMTX) proof-of-concept; IMA402 at 30% cORR, IMA401 29% in melanoma - Stock Titan

Immatics (NASDAQ: IMTX) proof-of-concept; IMA402 at 30% cORR, IMA401 29% in melanoma  Stock Titan

Immatics (NASDAQ: IMTX) proof-of-concept; IMA402 at 30% cORR, IMA401 29% in melanoma - Stock Titan

Click here to get full coverage on Immatics (IMTX) Shares Positive Phase 1a Clinical Trial Updates - GuruFocus

Immatics (IMTX) Shares Positive Phase 1a Clinical Trial Updates  GuruFocus

Immatics (IMTX) Shares Positive Phase 1a Clinical Trial Updates - GuruFocus

Click here to get full coverage on What MACD signals say about IMTX - Trade Volume Report & Real-Time Buy Signal Alerts - newser.com

What MACD signals say about IMTX - Trade Volume Report & Real-Time Buy Signal Alerts  newser.com

What MACD signals say about IMTX - Trade Volume Report & Real-Time Buy Signal Alerts - newser.com

Click here to get full coverage on Immatics (NASDAQ:IMTX) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat

Immatics (NASDAQ:IMTX) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS  MarketBeat

Immatics (NASDAQ:IMTX) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat

Click here to get full coverage on Immatics (IMTX) Reports Decline in Q3 Revenue Amidst Clinical Ad - GuruFocus

Immatics (IMTX) Reports Decline in Q3 Revenue Amidst Clinical Ad  GuruFocus

Immatics (IMTX) Reports Decline in Q3 Revenue Amidst Clinical Ad - GuruFocus

Click here to get full coverage on Immatics N.V. (NASDAQ:IMTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Immatics N.V. (NASDAQ:IMTX) Receives Consensus Rating of "Moderate Buy" from Brokerages  MarketBeat

Immatics N.V. (NASDAQ:IMTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Click here to get full coverage on Immatics Reports Q3 2025 Financial Results and Business Update - MSN

Immatics Reports Q3 2025 Financial Results and Business Update  MSN

Immatics Reports Q3 2025 Financial Results and Business Update - MSN

Click here to get full coverage on Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates  Yahoo Finance

Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on What does recent volatility data suggest for IMTX - Trade Ideas & Fast Moving Market Watchlists - newser.com

What does recent volatility data suggest for IMTX - Trade Ideas & Fast Moving Market Watchlists  newser.com

What does recent volatility data suggest for IMTX - Trade Ideas & Fast Moving Market Watchlists - newser.com

Click here to get full coverage on Will IMTX bounce back from current support - Quarterly Growth Report & AI Forecast Swing Trade Picks - newser.com

Will IMTX bounce back from current support - Quarterly Growth Report & AI Forecast Swing Trade Picks  newser.com

Will IMTX bounce back from current support - Quarterly Growth Report & AI Forecast Swing Trade Picks - newser.com

Click here to get full coverage on Strategies to average down on IMTX - 2025 Earnings Impact & Real-Time Volume Surge Alerts - newser.com

Strategies to average down on IMTX - 2025 Earnings Impact & Real-Time Volume Surge Alerts  newser.com

Strategies to average down on IMTX - 2025 Earnings Impact & Real-Time Volume Surge Alerts - newser.com

Click here to get full coverage on Earnings Flash (IMTX) Immatics Posts Q3 Net Loss 0.42 Euros a Share, vs. FactSet Est of 0.37 Euros Loss - MarketScreener

Earnings Flash (IMTX) Immatics Posts Q3 Net Loss 0.42 Euros a Share, vs. FactSet Est of 0.37 Euros Loss  MarketScreener

Earnings Flash (IMTX) Immatics Posts Q3 Net Loss 0.42 Euros a Share, vs. FactSet Est of 0.37 Euros Loss - MarketScreener

Click here to get full coverage on Fox Run Management L.L.C. Acquires New Position in Immatics N.V. $IMTX - MarketBeat

Fox Run Management L.L.C. Acquires New Position in Immatics N.V. $IMTX  MarketBeat

Fox Run Management L.L.C. Acquires New Position in Immatics N.V. $IMTX - MarketBeat

Click here to get full coverage on 25-Year Biopharma Veteran from Seagen, Gilead Joins Immatics as CFO for PRAME Cancer Therapy Launch - Stock Titan

25-Year Biopharma Veteran from Seagen, Gilead Joins Immatics as CFO for PRAME Cancer Therapy Launch  Stock Titan

25-Year Biopharma Veteran from Seagen, Gilead Joins Immatics as CFO for PRAME Cancer Therapy Launch - Stock Titan

Click here to get full coverage on Immatics: Taking Off On A PRAME Rocketship - Seeking Alpha

Immatics: Taking Off On A PRAME Rocketship  Seeking Alpha

Immatics: Taking Off On A PRAME Rocketship - Seeking Alpha

Click here to get full coverage on Guggenheim Maintains Immatics(IMTX.US) With Buy Rating, Raises Target Price to $19 - 富途牛牛

Guggenheim Maintains Immatics(IMTX.US) With Buy Rating, Raises Target Price to $19  富途牛牛

Guggenheim Maintains Immatics(IMTX.US) With Buy Rating, Raises Target Price to $19 - 富途牛牛

Click here to get full coverage on Investors Don't See Light At End Of Immatics N.V.'s (NASDAQ:IMTX) Tunnel - simplywall.st

Investors Don't See Light At End Of Immatics N.V.'s (NASDAQ:IMTX) Tunnel  simplywall.st

Investors Don't See Light At End Of Immatics N.V.'s (NASDAQ:IMTX) Tunnel - simplywall.st

Click here to get full coverage on Immatics (IMTX) Shows Promising Results with Anzu-cel in Uveal M - GuruFocus

Immatics (IMTX) Shows Promising Results with Anzu-cel in Uveal M  GuruFocus

Immatics (IMTX) Shows Promising Results with Anzu-cel in Uveal M - GuruFocus

Click here to get full coverage on Immatics (NASDAQ:IMTX) Stock Price Up 8% - Here's Why - MarketBeat

Immatics (NASDAQ:IMTX) Stock Price Up 8% - Here's Why  MarketBeat

Immatics (NASDAQ:IMTX) Stock Price Up 8% - Here's Why - MarketBeat

Click here to get full coverage on Investors in Immatics (NASDAQ:IMTX) have unfortunately lost 53% over the last year - Yahoo Finance

Investors in Immatics (NASDAQ:IMTX) have unfortunately lost 53% over the last year  Yahoo Finance

Investors in Immatics (NASDAQ:IMTX) have unfortunately lost 53% over the last year - Yahoo Finance

Click here to get full coverage on Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Raises Target Price to $23 - 富途牛牛

Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Raises Target Price to $23  富途牛牛

Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Raises Target Price to $23 - 富途牛牛

Click here to get full coverage on Immatics (IMTX) Appoints New CFO to Drive Strategic Initiatives - GuruFocus

Immatics (IMTX) Appoints New CFO to Drive Strategic Initiatives  GuruFocus

Immatics (IMTX) Appoints New CFO to Drive Strategic Initiatives - GuruFocus

Click here to get full coverage on Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo Finance

Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds?  Yahoo Finance

Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo Finance

Click here to get full coverage on We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth - simplywall.st

We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth  simplywall.st

We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth - simplywall.st

Click here to get full coverage on Immatics N.V. Appoints Venkat Ramanan, Ph.D. as Chief Financial Officer - Quiver Quantitative

Immatics N.V. Appoints Venkat Ramanan, Ph.D. as Chief Financial Officer  Quiver Quantitative

Immatics N.V. Appoints Venkat Ramanan, Ph.D. as Chief Financial Officer - Quiver Quantitative

Click here to get full coverage on We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth - Sahm

We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth  Sahm

We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth - Sahm

Click here to get full coverage on Biopharma firm Immatics misses Q3 collaboration revenue estimates, posts bigger loss - TradingView

Biopharma firm Immatics misses Q3 collaboration revenue estimates, posts bigger loss  TradingView

Biopharma firm Immatics misses Q3 collaboration revenue estimates, posts bigger loss - TradingView

Click here to get full coverage on Immatics price target raised to $23 from $19 at Mizuho - TipRanks

Immatics price target raised to $23 from $19 at Mizuho  TipRanks

Immatics price target raised to $23 from $19 at Mizuho - TipRanks

Click here to get full coverage on What data driven models say about IMTX’s future - July 2025 Short Interest & Technical Entry and Exit Tips - newser.com

What data driven models say about IMTX’s future - July 2025 Short Interest & Technical Entry and Exit Tips  newser.com

What data driven models say about IMTX’s future - July 2025 Short Interest & Technical Entry and Exit Tips - newser.com

Click here to get full coverage on Immatics Appoints Amie Krause as Chief People Officer - GlobeNewswire

Immatics Appoints Amie Krause as Chief People Officer  GlobeNewswire

Immatics Appoints Amie Krause as Chief People Officer - GlobeNewswire

Click here to get full coverage on Immatics Announces First Quarter 2025 Financial Results and Business Update - GlobeNewswire

Immatics Announces First Quarter 2025 Financial Results and Business Update  GlobeNewswire

Immatics Announces First Quarter 2025 Financial Results and Business Update - GlobeNewswire

Click here to get full coverage on Immatics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st

Immatics Second Quarter 2025 Earnings: Misses Expectations  simplywall.st

Immatics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st

Click here to get full coverage on Immatics Announces Second Quarter 2025 Financial Results and Business Update - GlobeNewswire

Immatics Announces Second Quarter 2025 Financial Results and Business Update  GlobeNewswire

Immatics Announces Second Quarter 2025 Financial Results and Business Update - GlobeNewswire

Click here to get full coverage on Immatics Appoints Venkat Ramanan as Chief Financial Officer - GlobeNewswire

Immatics Appoints Venkat Ramanan as Chief Financial Officer  GlobeNewswire

Immatics Appoints Venkat Ramanan as Chief Financial Officer - GlobeNewswire

Click here to get full coverage on Immatics Reports Q3 2025 Financial Results and Business Update - TipRanks

Immatics Reports Q3 2025 Financial Results and Business Update  TipRanks

Immatics Reports Q3 2025 Financial Results and Business Update - TipRanks

Click here to get full coverage on Immatics NV earnings missed by €0.28, revenue fell short of estimates - Investing.com

Immatics NV earnings missed by €0.28, revenue fell short of estimates  Investing.com

Immatics NV earnings missed by €0.28, revenue fell short of estimates - Investing.com

Click here to get full coverage on Immatics Reveals Promising Phase 1a Results for TCR Bispecifics - TipRanks

Immatics Reveals Promising Phase 1a Results for TCR Bispecifics  TipRanks

Immatics Reveals Promising Phase 1a Results for TCR Bispecifics - TipRanks

Click here to get full coverage on Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 - GlobeNewswire

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025  GlobeNewswire

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 - GlobeNewswire

Click here to get full coverage on Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewswire

Immatics Announces Full Year 2024 Financial Results and Business Update  GlobeNewswire

Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewswire

Click here to get full coverage on Mizuho reiterates Outperform rating on Immatics stock following Q2 results - Investing.com

Mizuho reiterates Outperform rating on Immatics stock following Q2 results  Investing.com

Mizuho reiterates Outperform rating on Immatics stock following Q2 results - Investing.com

Click here to get full coverage on Immatics NV Misses Revenue But Keeps Analyst Fans On Board - Finimize

Immatics NV Misses Revenue But Keeps Analyst Fans On Board  Finimize

IMTX

Price Chart

Key Statistics

Technicals

About IMTX

Latest News

Chardan Capital Reaffirms Buy Rating for Immatics (NASDAQ:IMTX) - MarketBeat

Chardan Capital Maintains Immatics N.V. (IMTX) Buy Recommendation - Nasdaq

Immatics (NasdaqCM:IMTX) Valuation Spotlight After Q3 Net Loss Expands - simplywall.st

Advanced Charts

Top Gainers

Top Losers